Genelux Co. (NASDAQ:GNLX – Get Rating) shares were up 4.1% during mid-day trading on Thursday . The company traded as high as $31.70 and last traded at $29.25. Approximately 8,146 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 147,528 shares. The stock had previously closed at $28.11.
Analyst Upgrades and Downgrades
Separately, Benchmark started coverage on shares of Genelux in a report on Wednesday, February 15th. They issued a "speculative buy" rating and a $10.00 price objective on the stock.
Genelux Stock Down 5.3 %
Genelux Company Profile
(Get Rating)
Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus.
Featured Articles
- Get a free copy of the StockNews.com research report on Genelux (GNLX)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ's Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.